X

Trial Profile

A Multi-center, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Licaminlimab for the Treatment of Dry Eye Disease

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Licaminlimab (Primary)
Indications Dry eyes
Focus Therapeutic Use
Acronyms RELIEF
Sponsors Oculis Pharma

Most Recent Events

10 Jun 2024 According to an Oculis Pharma media release, the company look forward to discussing these encouraging data with the FDA and advancing this program into Phase 3.
10 Jun 2024 Results presented in an Oculis Pharma Media Release.
10 Jun 2024 Primary endpoint (To evaluate the efficacy of licaminlimab in subjects with signs of dry eye disease) has been met, according to an Oculis Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com